Interestingly, all 22 patients without vulvar cancer relapse exhibited a decrease in PD-L1+ CD49f+ CD133+ CTC numbers during therapy (Fig. 4G; right panel; grey lines) and all 18 patients with relapse showed an increase in numbers of this CTC subpopulation (purple lines). The gene discussed is PROM1; the disease is vulva cancer.